Literature DB >> 28557280

CD8 expression in B chronic lymphocytic leukemia: A case of immuno-phenotypic aberrancy.

Mili Jain1, Rashmi Kushwaha1, Shailendra Prasad Verma2, Uma Shankar Singh1, Anil Kumar Tripathi2, Madhu Mati Goel1, Ashutosh Kumar1.   

Abstract

Immuno-phenotyping forms an integral part of laboratory work up of Chronic lymphocytic leukemia (CLL). Aberrant antigen expressions are a known phenomenon in leukemic blasts, however cross lineage antigen expression is rarely seen in mature B cell leukemia, the reported percentages varying from 1% to 3% in Europe and North America. CASE DETAILS: We report a case of Rai stage 1 CLL showing aberrant expression of CD8 on flow cytometry. The patient had stable disease at a follow up of 9 months with no requirement of initiation of treatment. DISCUSSION: CD8 expression in CLL is rare and approximately 120 cases have been reported from Western population. To the best of our knowledge, this is the first case to be reported from India. The prognostic significance has been variably reported from favorable to poor. At present, our case reflects the phenotypic heterogeneity of leukemia. Long term follow up and evaluation of more cases is required to predict the prognostic role in our patient population.
© 2017 International Clinical Cytometry Society. © 2017 International Clinical Cytometry Society.

Entities:  

Keywords:  B Cells; CLL; chronic lymphocytic leukemia; flow cytometry; immuno-phenotyping

Mesh:

Substances:

Year:  2017        PMID: 28557280     DOI: 10.1002/cyto.b.21535

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  1 in total

1.  A Cross Sectional Study on T Cells and Subsets in Chronic Lymphocytic Leukemia and their Association with Clinical Phenotype.

Authors:  Mili Jain; Anushree Rai; Rashmi Kushwaha; Geeta Yadav; Sanjay Mishra; Shailendra Prasad Verma; Uma Shankar Singh; Anil Kumar Tripathi; Ashutosh Kumar
Journal:  Indian J Hematol Blood Transfus       Date:  2021-01-21       Impact factor: 0.915

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.